Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study

BACKGROUND: Indacaterol is a novel once-daily ultra long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease. It is known that β(2)-agonists, like other adrenergic compounds, can prolong the QT-interval. This thorough QT/QTc study (as per ICH E14 guideline) evaluated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Khindri, Sanjeev, Sabo, Ronald, Harris, Stuart, Woessner, Ralph, Jennings, Simon, Drollmann, Anton F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116479/
https://www.ncbi.nlm.nih.gov/pubmed/21615886
http://dx.doi.org/10.1186/1471-2466-11-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116479/
https://www.ncbi.nlm.nih.gov/pubmed/21615886
http://dx.doi.org/10.1186/1471-2466-11-31

Ejemplares similares